Cognitive Research Market

Neuropeptide Y

A native 36-residue brain and sympathetic nerve peptide acting mainly at Y1, Y2 and Y5 receptors, studied in small intranasal trials for post-traumatic stress disorder and depression, with no approved product in any country.

NeuropeptideStressAppetiteIntranasalNot FDA Approved

Also referenced as: NPY, Neuropeptide tyrosine

Also appears in: Metabolic

Public product evidence No certificate records are bound to a tracked Neuropeptide Y product page A record counts here only when a vendor publishes a certificate against one of its own tracked Neuropeptide Y product pages. Other certificates naming this compound may still exist — search the wider certificate database.
Status
Research Market

This name primarily lives in the research market and should not be read like an approved pharmaceutical product.

Research area
Cognitive / nootropic research

Primary research area: Cognitive. Also surfaces under Metabolic for browsing and discovery.

Body systems
Brain · Hormones

Where the compound acts, as a browse axis. It is an editorial grouping for discovery, not a claim about labeled indications.

Aliases
2

NPY, Neuropeptide tyrosine

Signal depth
Medium

FDA label signal · 100 trials · 1000 PubMed results

Promising

Neuropeptide Y has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.

Neuropeptide Y has 8 name-matched clinical trials (highest phase: Phase 4) and 1000 PubMed-indexed publications and is not FDA-approved. 1 trial has posted results. Note: 4 retracted publications in the literature.

⚠ 4 retracted publications
Human data
Phase 3
Trial quality
Randomized
Outcomes
Clinical outcomes
Replication
Meta-analysis
Literature
Top-tier journals

Re-checked nightly against the registries — tracked since 2026-11-17. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-11-18 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →


What is Neuropeptide Y?

Neuropeptide Y is a native human peptide of 36 amino acids with the sequence Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Met-Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr and an amidated C-terminal tyrosine. It is cut from a 97-residue precursor that also releases the C-flanking peptide of neuropeptide Y, and the mature peptide occupies residues 29 to 64 of that precursor (UniProt P01303). The name records the tyrosine residues at both ends, tyrosine being Y in single-letter notation.

Tatemoto and colleagues isolated it from porcine brain and reported its structural similarity to peptide YY and pancreatic polypeptide, the two other members of the same family (Tatemoto et al., Nature, 1982;296(5858):659-660). In most mammals those three ligands act on four receptors, named Y1, Y2, Y4 and Y5 under the International Union of Pharmacology nomenclature (Michel et al., Pharmacological Reviews, 1998;50(1):143-150). The peptide is abundant in the limbic system and is also a co-transmitter in sympathetic nerves, so its biology spans appetite, anxiety, blood pressure and fat tissue at once.

Neuropeptide Y is not an analog or a development candidate but the endogenous ligand itself, synthesized unmodified and studied mainly as an intranasal solution. No product containing it has been approved in any country, the small human trials run so far were academic, and it circulates on the research-peptide market as a laboratory-grade powder.

How it works

  • Receptor family with opposing roles. Y1 and Y5 are postsynaptic receptors whose activation drives feeding and dampens anxiety-like behavior, while Y2 is largely a presynaptic autoreceptor that limits further release of the peptide; all four couple to inhibitory G proteins and lower cyclic AMP. Crystal structures of the human Y1 receptor bound to the antagonists UR-MK299 and BMS-193885, at 2.7 and 3.0 Å, defined how the peptide’s N-terminus engages the receptor, and the authors note that Y1 primarily mediates its effect on food intake (Yang et al., Nature, 2018;556(7702):520-524). Cryo-electron microscopy structures of Gi2-coupled Y1 and Y2 receptors later identified a sub-pocket that accounts for subtype selectivity (Shen et al., MedComm, 2024;5(7):e565).
  • Strongest known orexigenic signal in the hypothalamus. Injection into the rat paraventricular nucleus elicits large, immediate food intake, an effect first reported alongside pancreatic polypeptide and then characterized as a powerful stimulant of feeding behavior with a preference for carbohydrate (Clark et al., Endocrinology, 1984;115(1):427-429; Stanley et al., Proceedings of the National Academy of Sciences, 1985;82(11):3940-3943).
  • Anti-stress action in the brain and a pressor action outside it. Across animal models the peptide opposes behavioral consequences of stress with an effect size that exceeds other endogenous compounds, with the amygdala and hippocampus as the best-documented sites, Y1 agonism mimicking the effect and Y2 blockade producing an indistinguishable one (Heilig, Neuropeptides, 2004;38(4):213-224). In the periphery the same peptide released from sympathetic nerves produces vasoconstriction that resists alpha-adrenoceptor blockade (Lundberg et al., Acta Physiologica Scandinavica, 1982;116(4):393-402), and Y1-preferring analogs raise blood pressure (Shen et al., MedComm, 2024;5(7):e565).
  • Short peripheral life and a receptor-switching metabolite. Dipeptidyl peptidase IV removes the N-terminal Tyr-Pro dipeptide to give the 3-36 fragment, which loses Y1 binding while retaining Y2 activity, so enzymatic clipping redirects the peptide to a different receptor rather than inactivating it (Mentlein et al., Regulatory Peptides, 1993;49(2):133-144). Stress-released peptide acting on Y2 receptors in abdominal fat also drives angiogenesis, adipocyte proliferation and abdominal obesity in mice (Kuo et al., Nature Medicine, 2007;13(7):803-811).

Research status

Human stress and mood biology. Plasma concentrations rise sharply in soldiers undergoing military survival training and track subjective distress (Morgan et al., Biological Psychiatry, 2000;47(10):902-909). Combat veterans with post-traumatic stress disorder showed low baseline and low yohimbine-stimulated plasma levels (Rasmusson et al., Biological Psychiatry, 2000;47(6):526-539), and a later comparison attributed the reduction to trauma exposure rather than to the diagnosis itself (Morgan et al., Biological Psychiatry, 2003;54(10):1087-1091). Cerebrospinal fluid concentrations were proposed as a marker for major depression as early as 1988 (Widerlov et al., Journal of Psychiatric Research, 1988;22(1):69-79). A common promoter variant, rs16147, accounts for more than half of the variation in expression in vivo, and lower expression predicts greater emotion-induced amygdala activation and higher trait anxiety (Zhou et al., Nature, 2008;452(7190):997-1001).

Intranasal dosing in healthy volunteers. A Mount Sinai study gave low-dose and high-dose intranasal peptide against placebo in 10 healthy male volunteers, completing its primary measurements in December 2010 and establishing the route every later human study used (NCT00748956).

Post-traumatic stress disorder. The single published controlled trial was a crossover, single ascending dose study at Mount Sinai in 26 randomized patients, dosed in five cohorts of 1.4, 2.8, 4.6, 6.8 and 9.6 mg with placebo on a separate day one week apart, with assessments after a trauma script provocation. Twenty-four completed both treatment days, the peptide was tolerated up to and including the highest dose, and there was a significant treatment-by-dose interaction favoring it over placebo on the Beck Anxiety Inventory (F1,20 = 4.95, P = .038) but no significant interaction on the State-Trait Anxiety Inventory (Sayed et al., International Journal of Neuropsychopharmacology, 2018;21(1):3-11). The registry lists it as phase 1, started in December 2012 and completed in January 2016 (NCT01533519). A follow-on phase 1/2 study at a level two trauma center, planned for 117 participants with a start date of November 1, 2019, carries a registry status of unknown, a last update posted on August 28, 2019 and no results (NCT04071600).

Major depressive disorder. Thirty patients on a stable antidepressant dose insufflated 6.8 mg of the peptide (12 patients) or placebo (18 patients). The prespecified primary endpoint, change in the Montgomery-Asberg Depression Rating Scale at 48 hours, was not met. At 24 hours the scale fell 10.3 points against 5.6 on placebo (group-by-time F = 3.26, DF = 1,28; P = .04; Cohen’s d = 0.67), and at 5 hours it fell 7.1 against 3.5 (P = .05; d = 0.61), leading the authors to call for dose-ranging and repeated-dosing trials (Mathe et al., International Journal of Neuropsychopharmacology, 2020;23(12):783-790).

Receptor-targeted small molecules failed in obesity. Merck tested MK-0557, a selective oral Y5 antagonist, in a 52-week, multicenter, randomized, placebo-controlled trial of 1,661 overweight and obese patients after positron-emission tomography work supported a 1 mg daily dose; the weight loss reached statistical significance at 52 weeks but was not clinically meaningful, and the authors concluded that targeting Y5 alone is unlikely to produce efficacy (Erondu et al., Cell Metabolism, 2006;4(4):275-282). Two further trials confirmed the result: in 359 patients randomized after a very-low-calorie diet, the compound limited regain by 1.6 kg relative to placebo over 52 weeks, a significant but small difference (Erondu et al., Obesity, 2007;15(4):895-905), and in 497 patients it did not augment the weight loss produced by orlistat or sibutramine (Erondu et al., Obesity, 2007;15(8):2027-2042). A second Y5 antagonist, velneperit from Shionogi, was carried into obesity testing and still listed among pipeline anti-obesity agents in 2018, but it has not been approved anywhere (Srivastava et al., Current Obesity Reports, 2018;7(2):147-161).

Current human work uses the peptide as a physiological probe. A Vanderbilt phase 4 study infused it in 18 patients with type 2 diabetes to measure its contribution to vasoconstriction during dipeptidyl peptidase IV inhibition (NCT02639637), and an early phase 1 study at UT Southwestern on sympathetic transduction in obesity-associated hypertension lists an estimated primary completion of December 31, 2026 (NCT04838678).

Preclinical direction. A single intranasal infusion prevented and reversed behavioral impairments in the rat single prolonged stress model of post-traumatic stress disorder (Serova et al., Neuroscience, 2013;236:298-312; Serova et al., European Neuropsychopharmacology, 2014;24(1):142-147), and later work extended the effect to sustained extinction of fear memory (Sabban et al., Journal of Neuroendocrinology, 2023;35(11):e13279). Female animals required higher doses or pretreatment with a dipeptidyl peptidase IV inhibitor, and a 2026 review of the route recommends aqueous delivery in water rather than saline and separate analysis by sex (Sabban et al., Neuropeptides, 2026;117:102605). Intranasal dosing also suppressed food intake in diet-induced obese mice through Y2 receptors (Haag et al., Neurotherapeutics, 2026;24(1):e01100), and spinal Y1 interneurons remain an active analgesia target (Nie et al., Journal of Internal Medicine, 2025;298(4):280-296).

Regulatory record. Drugs@FDA holds no application for the peptide, and no marketing authorization exists for it in the US or abroad as of November 2026. Two over-the-counter homeopathic liquid listings in DailyMed, with label dates in February 2026, name it among a long list of ingredients; such listings are registrations of unapproved homeopathic drugs rather than approvals.

Common dosage forms

  • Intranasal solution. The presentation used in every human study: a sterile aqueous solution delivered by a nasal device under investigator supervision at an academic site.
  • Solution for intravenous infusion. The form used in cardiovascular and autonomic probe studies, prepared by a research pharmacy for a monitored session.
  • Lyophilized powder. The research-market presentation, a laboratory-grade freeze-dried solid in small vials, with no approved or compounded clinical presentation anywhere.

Key considerations

  • Regulatory status. The Research Market status reflects the absence of any approved neuropeptide Y product in the US or abroad and the absence of a registered sponsor-led development program aimed at approval. The two published controlled trials were investigator-initiated and neither has a successor in the registries.
  • The human efficacy evidence is one small positive signal and one missed endpoint. The post-traumatic stress disorder study randomized 26 patients to single doses and found a dose-dependent effect on one anxiety scale and not the other, and the depression trial of 30 patients missed its prespecified 48-hour endpoint while separating from placebo at earlier time points. Both authors’ groups described the results as grounds for dose-ranging and repeated-dosing work, which has not been published.
  • Receptor pharmacology cuts in several directions at once. Y1 and Y5 agonism drives feeding while the same receptors carry the anxiolytic effect, and the dipeptidyl peptidase IV metabolite shifts activity from Y1 to Y2. A systemic dose therefore cannot be expected to reproduce a single targeted effect, which is the main argument for nose-to-brain delivery.
  • Cardiovascular effects are intrinsic to the molecule. It is a sympathetic co-transmitter that causes vasoconstriction unaffected by alpha-adrenoceptor blockade, and Y1-preferring analogs raise blood pressure, so blood-pressure effects are a predictable consequence of peripheral exposure rather than an incidental finding.
  • Naming. Neuropeptide Y, NPY and neuropeptide tyrosine denote the same 36-residue peptide; NPY(3-36) is its dipeptidyl peptidase IV metabolite and not an equivalent. MK-0557 and velneperit are oral Y5 receptor antagonists, the opposite pharmacology, and peptide YY and pancreatic polypeptide are related family members with their own receptor preferences.